Patients and study design
non-diabetic kidney disease
MAY, TYPE 1 DIABETES
DELIGHT was a double-blind, placebo-controlled, multicenter trial that enrolled 461 patients from nine countries. The study was conducted from July 2015 to May 2018. Methods and results were previously published [Excluding criteria included a diagnosis of type 1 diabetes and non-diabetic kidney disease. Patients with hemoglobin < 9 g/dL before screening or long-term use of glucocorticoids were also excluded. All participants provided written informed consent. Participants were offered separate and optional informed consent to collect additional blood or urine samples for future biomarker research. DELIGHT trial was conducted according to the Declaration of Helsinki, registered with clinicaltrials.gov (NCT02547935), and approved by an ethics committee at each site.